Use of RLI-15 a clinical grade fusion protein with IL-15 superagonistic activity for the activation of anti-tumor immune response

0521311 - MBÚ 2020 US eng A - Abstrakt
Adkins, I. - Sadílková, I. - Hradilová, N. - Tomala, Jakub - Tomalová, Barbora - Kovář, Marek - Mikysková, R. - Reiniš, Milan - de Martynoff, G. - Bechard, D. - Moebius, U. - Spíšek, R.
Use of RLI-15 a clinical grade fusion protein with IL-15 superagonistic activity for the activation of anti-tumor immune response.
Cancer Research. American Association for Cancer Research. Roč. 78, 13 S (2018). ISSN 0008-5472. E-ISSN 1538-7445.
[Annual Meeting of the American-Association-for-Cancer-Research (AACR). 14.04.2018-18.04.2018]
Institucionální podpora: RVO:61388971
Klíčová slova: RLI-15 * IL-15 * carcinoma
Obor OECD: Microbiology

RLI-15, a superagonist fusion protein of interleukin (IL)-15 and the IL-15 receptor α (IL-15Rα) sushi+ domain represents a promising candidate for the induction of anti-tumor immunity. RLI-15 was designed to bypass the need of endogenous IL-15Rα, thereby leveraging the activity of IL-15 in vivo on target immune cells. RLI-15 stimulates the proliferation and the cytotoxic activity of natural killer (NK) cells and memory CD8+ T cells with no significant expansion and activation of regulatory T cell compartment. RLI-15 was previously shown to exhibit a potent anti-metastatic activity in B16F10 melanoma and Renca renal cell carcinoma mouse models.
Trvalý link: http://hdl.handle.net/11104/0305937